MicroRNAs are a key factor in the globalization of tumor-host relationships
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13431Keywords:
biomarker, epigenetic regulation, microRNA., tumor-host relationshipsAbstract
Summary. A new round of molecular oncology development in the post-genomic era significantly changes the conventional understanding of the nature and origin of the malignant process. Increasingly, fundamental phenomena are emerging that change the “canonical” views of the dominant role of gene mutations that contribute to the uncontrolled proliferation and emergence of heterogeneous malignant cells. Recent numerous studies have shown that significant variability in the initiation, proliferation and control of the apoptotic program of tumor cells is due to numerous epigenetic processes, including the level of expression of microRNAs (miRNAs). This paper reviews the literature data and presents the results of own research in which miRNAs have been found to form a molecular phenotype for malignancy. Their role as a “conductor” of the functioning of a genetic-epigenetic orchestra that coordinates various aspects of malignancy has been suggested. MiRNAs have been shown to be an active participant in balancing mechanisms in the development of controversial processes in breast cancer cell lines of varying degrees of malignancy. The analysis of the literature data and the own studies of the expression profile of only a few miRNAs suggests that scientists and clinicians have received a new marker and a target that simultaneously plays the role of an active insider in both the oncogene-oncosuppressor relationship and in the globalization of this process at the tumor-host level. Further investigation of the “alarm” marker in this network will allow to reconsider the molecular genetic classification of neoplastic disease, which will provide the development of a new strategy for cancer therapy.
References
Chekhun VF. The concept “Tumor and host” in the post-genomic era. Exp Oncol 2010; 32: 120–4.
Feng F, Zhu X, Wang C, et al. Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells. Cancer Cell Int 2018; 18: 127.
Widschwendter M, Jones A, Evans J, et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol 2018; 15: 292–309.
Carden T, Singh B, Mooga V, et al. Epigenetic modification of miR-663 controls mitochondria-to-nucleus retrograde signaling and tumor progression. Biol Chem 2017; 292: 20694–706.
Long-Cheng Li, Steven T. Okino, et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 2006; 103: 17337–42.
Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820–3.
Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684–9.
Fishel R, Lescoe M, Rao M, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027–38.
Papadopoulos N, Nicolaides N, Wei Y, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625–9.
Nowell P, Hungerford DA. Minute chromosome in chronic granulocytic leukemia (abstract). Science 1960; 132: 1497.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309–22.
Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011; 30: 3391–403.
Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007; 26: 5395–407.
Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18: 2315–35.
Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21–33.
Chekhun VF, Kulik GI, Yurchenko OV, et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2006; 231: 87–93.
Sharma G, Mirza S, Parshad R, et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 2010; 43: 373–9.
Toth M, Boros IM, Balint E. Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci 2012; 103: 659–69.
Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632–42.
Shen M, Rothman N, Berndt SI, et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung cancer 2005; 49: 299–309.
Kisseljova NP, Kisseljov FL. DNA demethylation and carcinogenesis. Biochemistry (Mosc) 2005; 70: 743–52.
Kovalchuk O, Tryndyak VP, Montgomery B, et al. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007; 6: 2010–8.
D’Alessio AC, Szyf M. Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 2006; 84: 463–76.
Penna E, Orso F, Taverna D. miR-214 as a key hub that controls cancer networks: small player, multiple functions. J Invest Dermatol 2015; 135: 960–9.
He H, Zhang H, Li Z, et al. miRNA-214: expression, therapeutic and diagnostic potential in cancer. Tumori 2015; 101: 375–83.
Wen R, Umeano AC, Essegian DJ, et al. Role of microRNA-410 in molecular oncology: A double edged sword. J Cell Biochem 2018; 119: 8737–42.
Abak A, Amini S, Sakhinia E, Abhari A. MicroRNA-221: biogenesis, function and signatures in human cancers. Eur Rev Med Pharmacol Sci 2018; 22: 3094–117.
Soni M, Patel Y, Markoutsa E, et al. Autophagy, cell viability, and chemoresistance are regulated by miR-489 in breast cancer. Mol Cancer Res 2018; 16:1348–60.
Al-Khalaf HH, Aboussekhra A. p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1. Mol Carcinog 2017; 56: 985–99.
Dellago H, Bobbili MR, Grillari J. MicroRNA-17-5p: At the crossroads of cancer and aging — A mini-review. Gerontology 2017; 63: 20–8.
Li D, Wang H, Song H, et al. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. Oncotarget 2017; 8: 85276–89.
Sharma T, Hamilton R, Mandal CC. miR-214: a potential biomarker and therapeutic for different cancers. Future Oncol 2015; 11: 349–63.
Takahashi RU, Miyazaki H, Ochiya T. The Roles of microRNAs in breast cancer. Cancers (Basel) 2015; 7: 598–616.
Manz DH, Blanchette NL, Paul BT, et al. Iron and cancer: recent insights. Oncogene 2015; 34: 3839–47.
Juan Yu, Lei Wang, Haiping Yang, et al. Rab14 suppression mediated by MiR-320a inhibits cell proliferation, migration and invasion in breast cancer. J Cancer 2016; 7: 2317–26.
Teoh SL, Das S. The role of microRNAs in diagnosis, prognosis, metastasis and resistant cases in breast cancer. Curr Pharm Des 2017; 23: 1845–59.
Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics 2014; 2014: 970607.
Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol 2014; 24: R762–76.
Sangokoya C, Doss JF, Chi J-T. Iron-responsive miR-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet 2013; 9: e1003408.
Chen J, Chen Z, Huang J, et al. Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling. Oncol Lett 2018; 15: 3017–23.
Hasegawa T, Adachi R, Iwakata H, et al. ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer. FEBS Open Bio 2017; 7: 1154–65.
Ganju A, Khan S, Hafeez BB, et al. miRNA nanotherapeutics for cancer. Drug Discov Today 2017; 22: 424–32.
Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–11.
Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006; 25: 6156–62.
Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6(5): 376–85.
Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298–307.
Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745–52.
Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731–43.
Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83–6.
Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev 2007; 21: 578–89.
Karp X, Ambros V. Developmental biology. Encountering microRNAs in cell fate signaling. Science 2005; 310: 1288–9.
Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet 2004; 20: 617–24.
Hatfield SD, Shcherbata HR, Fischer KA, et al. Stem cell division is regulated by the microRNA pathway. Nature 2005; 435: 974–8.
Linsley PS, Schelter J, Burchard J, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 2007; 27: 2240–52.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682–8.
Jay C, Nemunaitis J, Chen P, et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007; 26: 293–300.
Li CY, Xiong DD, Huang CQ, et al. Clinical value of miR-101-3p and biological analysis of its prospective targets in breast cancer: A study based on the cancer genome atlas (TCGA) and bioinformatics. Med Sci Monit 2017; 23: 1857–71.
Nikitina AS, Sharova EI, Danilenko SA, et al. Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients. Oncotarget 2017; 8: 32990–3001.
Jia Jia Chan, Zhi Hao Kwok, Xiao Hong Chew, et al. A FTH1 gene:pseudogene:microRNA network regulates tumorigenesis in prostate cancer. Nucleic Acids Res 2018; 46: 1998–2011.
Bose S, Tholanikunnel TE, Reuben A, et al. Regulation of nucleolin expression by miR-194, miR-206, and HuR. Mol Cell Biochem 2016; 417: 141–53.
Stephen Safe. MicroRNA-specificity protein (Sp) transcription factor interactions and significance in carcinogenesis. Curr Pharmacol Rep 2015; 1: 73–8.
Abba ML, Patil N, Leupold JH, et al. MicroRNAs as novel targets and tools in cancer therapy. Cancer Lett 2017; 387: 84–94.
Guen VJ, Gamble C, Lees JA, Colas P. The awakening of the CDK10/Cyclin M protein kinase. Oncotarget 2017; 8: 50174–86.
Yang SJ, Yang SY, Wang DD, et al. The miR-30 family: Versatile players in breast cancer. Tumour Biol 2017; 39: 1010428317692204.
Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 2006; 33: 167–73.
Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005; 65: 3509–12.
Lamy P, Andersen CL, Dyrskjøt L, et al. Are microRNAs located in genomic regions associated with cancer? Br J Cancer 2006; 95: 1415–8.
Chekhun VF, Lukianova NY, Chekhun SV, et al. Association of CD44+CD24−/low with markers of aggressiveness and plasticity of cell lines and tumors of patients with breast cancer. Exp Oncol 2017; 39: 203–11.
Chekhun VF, Zalutskii IV, Naleskina LA, et al. Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells with varying degrees of malignancy and sensitivity of cytostatics. Exp Oncol 2015; 37: 181–6.
Grober OMV, Mutarelli M, Giurato G, et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC genomics 2011; 12: 36.
Castellano L, Giamas G, Jacob J, et al. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 2009; 106: 15732–7.
Lupini L, Bassi C, Ferracin M, et al. miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Front Genet 2013; 4: 64.
Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, et al. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One 2012; 7: e31904.
Yu Z, Tozeren A, Pestell RG. Function of miRNAs in tumor cell proliferation. In: Alahari S., ed. MicroRNA in Cancer. Dordrecht: Springer Science + Business Media Netherlands 2013; 13–27.
Ferrari-Amorotti G, Chiodoni C, Shen F, et al. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. Neoplasia 2014; 16: 1047–58.
Wang JY, Zhang Q, Wang DD, et al. MiR-29a: a potential therapeutic target and promising biomarker in tumors. Biosci Rep 2018; 38: pii: BSR20171265.
Liu Y, Zhang J, Sun X, et al. Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer. Oncotarget 2017; 8: 39559–70.
Yan B, Guo Q, Fu FJ, et al. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther 2015; 8: 539–48.
Marilina García-Aranda, Maximino Redondo. Protein kinase targets in breast cancer. Int J Mol Sci 2017; 18: 2543.
Penfornis P, Vallabhaneni KC, Whitt J, Pochampally R. Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. Int J Cancer 2016; 138: 14–21.
Wen Li, Yue Yang, Zhaoyu Ba, et al. MicroRNA-93 regulates hypoxia-induced autophagy by targeting ULK1. Oxid Med Cell Longev 2017; 2017: 2709053.
Roscigno G, Puoti I, Giordano I, et al. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget 2017; 8: 19507–21.
Al-Khalaf HH, Amir M, Al-Mohanna F, et al. Obesity and p16INK4A downregulation activate breast adipocytes and promote their protumorigenicity. Mol Cell Biol 2017; 37: pii: e00101–17.
Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: Cell-to-cell mediators of metastasis. Cancer Cell 2016; 30: 836–48.
Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, et al. Micro-RNAs as potential predictors of response to breast cancer systemic therapy: Future clinical implications. Int J Mol Sci 2017; 18: pii: E1182.
Bahrami A, Aledavood A, Anvari K, et al. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. J Cell Physiol 2018; 233: 774–86.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
